What is Quantum Pathology?
Quantum Pathology operates as a premier, independent laboratory entity, delivering a sophisticated suite of diagnostic services that span dermatopathology, molecular pathology, and urologic pathology, among other specialized fields. The company distinguishes itself through a rigorous focus on technological integration and rapid diagnostic turnaround times, which are critical for modern clinical decision-making. By maintaining a board-certified staff and fostering collaborative relationships with healthcare providers, Quantum Pathology serves as a vital link in the patient care continuum, providing the precision required for effective treatment planning across diverse medical disciplines.
How much funding has Quantum Pathology raised?
Quantum Pathology has raised a total of $930K across 2 funding rounds:
Debt
$350K
Debt
$580K
Debt (2020): $350K with participation from PPP
Debt (2021): $580K led by PPP
Key Investors in Quantum Pathology
PPP
Public-Private Partnership
What's next for Quantum Pathology?
With the recent influx of capital, Quantum Pathology is well-positioned to accelerate its strategic initiatives, likely focusing on the modernization of its molecular pathology platforms and the expansion of its national laboratory network. The company's reliance on debt-based financing suggests a focus on scaling existing operations and optimizing service delivery models to meet the rising demand for high-complexity diagnostic testing. Moving forward, the firm will likely prioritize the integration of advanced digital pathology tools and the further refinement of its customer service infrastructure to maintain its status as a preferred partner for medical professionals seeking reliable, high-throughput laboratory services.
See full Quantum Pathology company page
